H. Lundbeck AS (CHIX:HLUNBC) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HLUNBC H. Lundbeck AS CHIX:HLUNBC
71 GF Score
Price kr43.82
GF Value kr44.76
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is H. Lundbeck AS Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

CHIX:HLUNBC
71GF Score
H. Lundbeck AS CHIX:HLUNBC
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (CHIX:HLUNBC) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of kr43.82 is trading 2.1% below its estimated GF Value™ of kr44.76. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for CHIX:HLUNBC:

  • Total Noninterest Expense:
  • GF Value™: kr44.76 vs. price of kr43.82 (2.1% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CHIX:HLUNBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
H. Lundbeck A/S is a Danish pharmaceutical company focused on brain health, specializing in the research, development, and commercialization of treatments for central nervous system disorders. Its portfolio spans antidepressants, antipsychotics, and antiepileptics, with key products including Abilify Maintena and Rexulti for schizophrenia and adjunctive depression, Brintellix/Trintellix for major depressive disorder, Northera for neurogenic orthostatic hypotension, Onfi and Sabril for epilepsy, and Vyepti for migraine prevention. Lundbeck also markets alcohol dependence and Alzheimer's-related therapies. The company sells primarily to hospitals, psychiatrists, neurologists, and other specialists through its own sales forces and partnerships, with North America generating the largest share of revenue, followed by Europe and international markets including Asia. Revenue comes mainly from product sales, supplemented by licensing and collaboration income, and Lundbeck invests heavily in late-stage clinical research and pipeline expansion.
71GF Score

Get the complete analysis for CHIX:HLUNBC

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr43.82
Price
kr44.76
GF Value